Loading...

BCTX BRIACELL THERAPEUTICS CORP Other Situations 8-K Filing

BRCL

BCTX

BRIACELL THERAPEUTICS CORP

(BCTX)

2023 8-K

Financial Report Filed

Share Consolidation

Equity Offerings

Financial Statements

Equity Offerings

Financial Filing

Nasdaq Compliance

Annual Meeting Results

Share Consolidation

Share Consolidation

Meeting Reschedule

Financial Filing

Public Offering

Director Resignation

Financial Disclosure

Clinical Trial Success

Positive Announcements

Financial Statements

Securities Purchase Agreements

Financial Statements

Annual General Meeting of S...

Financial Statements

Announcement of Phase 2 Stu...

Financial Statements and Ex...

Spin-out Transaction

Spin-out Transaction

Shareholder Meeting Results

FDA Approval for Bria-IMTTM...

Spin-off Agreement

Equity Issuance

Agreement and Stock Purchase

Clinical Data Presentation

Reorganization Plan

Promising Survival Data fro...

Amendment and Shareholder M...

Regulation FD Disclosure

Investigation Announcement

FDA Meeting Feedback

Patent Issuance and FDA Gui...

External Links:

BriaCell Therapeutics Corp. announced a new remarkable responder in their Phase 2 study of the Bria-IMT combination regimen, with additional survival updates and clinical data sets to be presented at the San Antonio Breast Cancer Symposium.

AI Assistant

BRIACELL THERAPEUTICS CORP

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.